Padcev (Enfortumab Vedotin)
Padcev™ (enfortumab vedotin) is a treatment option for some patients with locally advanced or metastatic bladder cancer. It was approved by the US Food and Drug Administration in December 2019.
How does Padcev work?
Enfortumab vedotin targets specific cancer cells by locking onto the Nectin-4 molecule often found in bladder cancers. It is called a Nectin-4-directed antibody and microtubule inhibitor conjugate, which means it combines an antibody with a chemotherapy medication. The antibody portion helps to find and attach to the bladder cancer cells containing the Nectin-4 molecule. Once attached, the chemotherapy portion is released to attack the cancer cell.1
Who can receive Padcev?
Enfortumab vedotin may be used in the treatment of patients with locally advanced or metastatic bladder cancer who received prior treatment with either a PD-1 inhibitor or a PD-L1 inhibitor (forms of immunotherapy), and platinum-based chemotherapy. Locally advanced typically means the cancer has spread beyond the bladder within the bladder region (i.e. to nearby lymph nodes) or has become too large to be removed by surgery. Metastatic means the cancer cells have spread to other parts of the body.
What are the possible side effects of Padcev?
The most common side effects for people taking enfortumab vedotin include:1
- Peripheral neuropathy (nerve damage that causes tingling or numbness)
- Decreased appetite
- Hair loss
- Changes in taste
- Dry eye
- Dry skin
More serious side effects
Enfortumab vedotin can cause some serious side effects. Your healthcare provider will talk with you about the signs and symptoms of the serious side effects that treatment with enfortumab vedotin can cause. These can include:1
- High blood sugar
- Tingling or numbness in the feet and/or hands
- Problems with the eyes, such as vision changes
- Rash or skin reaction
- Infusion site reactions
If you experience any of the symptoms of serious side effects, let your healthcare provider know immediately. Quick treatment can potentially help keep the side effects from getting worse. This is not an exhaustive list of all potential side effects of enfortumab vedotin. Talk to your healthcare provider or pharmacist for further information.
Things to know about Padcev
Because of its potential for serious side effects, people receiving treatment with enfortumab vedotin should be watched closely. The amount of enfortumab vedotin someone receives may need to be stopped or reduced if patients experience certain serious side effects.1
Enfortumab vedotin should not be taken by pregnant women
Enfortumab vedotin can cause harm to a developing fetus and should not be taken by women who are pregnant. While receiving enfortumab vedotin, males with female partners who can become pregnant, and females who can become pregnant, should both use contraceptives during treatment and for a period of time after completing treatment (patients should discuss appropriate birth control methods, and how long they need to use them, with their doctor). Females should not breastfeed during enfortumab vedotin treatment and for at least three weeks following the final dose.1
Patients receiving enfortumab vedotin should talk to their doctor about any other medications (prescription and over-the-counter), herbal remedies, and any supplements they are taking, as well as any other health conditions. Patients should talk to their doctor if they have any questions, or if they have questions regarding their enfortumab vedotin regimen.
Padcev is made by Astellas Pharma US Inc. Read the prescribing information to learn more.2